Chemistry project lead for hit-to-lead efforts on novel target for frontotemporal dementia• Coordinated project efforts with biology and DMPK • Triaged screening hits and designed hybrid analogs using structure-based docking in MOE software• Directed synthesis of targets at 2 CROs

Co-inventor of gamma secretase modulator preclinical candidate for Alzheimer’s disease and co-inventor of alpha 7 nicotinic receptor agonist preclinical candidate for cognitive enhancement. • Designed key analogs that advanced the SAR towards the candidates• Directed two 4 FTE teams at European CRO, and co-led 16 FTE team at Asian CRO. Developed novel synthetic routes for lead series and prepared novel analogs• Managed scale-up of both candidates on 400 g scale at Asian CRO• Compiled and edited experimental sections for 6 patent applications. Co-inventor on all 6 applications.Participated in planning process for potential internal chemistry labs• Identified and evaluated equipment and instruments for internal lab setup• Chemistry rep on committee for implementation of new electronic lab notebook.

Part of the discovery team of LX2761, locally acting SGLT1 inhibitor, clinical candidate for diabetes• Played support role to chemistry lead .• Made key laboratory contributions to the discovery of the clinical candidate• Co-inventor on composition of matter patentProject manager for collaboration with 6 FTE team at SAI Life Sciences in India• Coordinated between internal group leaders and SAI chemists for the scale-up of key intermediates and reference compounds.• Reviewed reports and analytical data, conducted telecoms, and assisted in trouble-shooting of difficult reactions.Chemistry lead for a dry AMD ophthalmology project targeting an ion channel• Performed hit triage from HTS screen• Identified a lead series through hit-to-lead efforts, progressed potency from micromolar to low nanomolar• Achieved in vivo proof-of-concept in an animal model of dry AMD• Supervised 2 direct reports, one at associate level and one at scientist level

Chemistry lead for the discovery team of LX7101, LIM-kinase inhibitor, completed phase 1 clinical trials for glaucoma• Directed chemistry efforts toward the identification of the clinical candidate• Coordinated discovery efforts with leads from ophthalmology, pharmaceutical discovery, and DMPK• Presented chemistry updates in working group meetings and to senior management• Prepared chemistry section of composition of matter patent, co-inventor on patent• Supervised 2 associate level direct reports• Maintained active presence in the lab throughout project

Key contributor to the discovery of Sotagliflozin (LX4211), first-in-class dual SGLT1/2 inhibitor, phase 3 for diabetes.• Developed stereoselective route to D-xylosides that enabled the discovery of the clinical candidate• Supervised associate level direct report who first prepared both the first compound in the primary series and the clinical candidate• Helped develop improved 12 step stereoselective synthesis of the compound, including novel chemistry for the stereoselective formation of beta thioglycosides• Co-inventor on both the composition of matter patent and the process patent• Identified backup series of aza sugars

Advisor: Professor Erik J. SorensenTotal synthesis of Abyssomicin C